Maxim Group Sticks to Their Buy Rating for BioLife Solutions (BLFS)

In a report released today, Jason McCarthy from Maxim Group maintained a Buy rating on BioLife Solutions, with a price target of $34.00.

Claim 70% Off TipRanks Premium

• Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
• Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential

McCarthy covers the Healthcare sector, focusing on stocks such as Aprea Therapeutics, Co-Diagnostics, and Plus Therapeutics. According to TipRanks, McCarthy has an average return of -17.7% and a 28.26% success rate on recommended stocks.

In addition to Maxim Group, BioLife Solutions also received a Buy from TipRanks – Google’s Google Medical – Instruments and Supplies in a report issued on March 3. However, yesterday, TipRanks – OpenAI reiterated a Hold rating on BioLife Solutions (NASDAQ: BLFS).

Based on BioLife Solutions’ latest earnings release for the quarter ending December 31, the company reported a quarterly revenue of $18.79 million and a net profit of $3.54 million. In comparison, last year the company had a net profit of $12.46 million

Based on the recent corporate insider activity of 119 insiders, corporate insider sentiment is negative on the stock. This means that over the past quarter there has been an increase of insiders selling their shares of BLFS in relation to earlier this year. Most recently, in December 2025, Amy DuRoss, a Director at BLFS sold 2,000.00 shares for a total of $49,200.00.